 |
|
|
| |
Socio-structural Factors Surrounding Long Acting Injectable ART: A Qualitative Study Among PLHIV Participating in a Phase II Study of Cabotegravir + Rilpivirine (LATTE-2) in the US and Spain
|
| |
| |
Reported by Jules Levin
EACS - 16th European AIDS Conference, October 25-27, 2017. Milan
Federico Pulido,1Gary Richmond,2Maria-Luisa Montes,3Miguel Gorgolas,4 Cynthia Brinson,5Miranda Murray,6David Margolis,7Andrea Mantsios,8Deanna Kerrigan8
1Hospital Universitario Doce de Octubre, Madrid, Spain; 2Gary J Richmond MD PA, Ft Lauderdale, FL, USA; 3Hospital Universitairo La Paz, IdiPAZ, Madrid, Spain; 4Hospital Fundacion Jimenez Diaz, Madrid, Spain; 5Central Texas Clinical Research Corporation, Austin, TX, USA; 6ViiV Healthcare, London, United Kingdom; 7ViiV Healthcare, Research Triangle Park, NC, USA; 8Department of Health, Behavior & Society, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
References: 1. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438. 2. Kacanek D, Angelidou K, Williams PL, et al. Psychiatric symptoms and antiretroviral non-adherence in US youth with perinatal HIV: a longitudinal study. AIDS. 2015;29(10):1227-1237. 3. Katz IT, Ryu AE, Onuegbu AG, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc. 2013;16(Suppl 2):18640. 4. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499-1510.
|
| |
|
|
|
|
|
